Luspatercept
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Luspatercept: From Beta-Thalassemia to Monosomy X
One-Sentence Summary
Luspatercept was originally used to treat beta-thalassemia and related hemoglobin disorders. The TxGNN model predicts it may be effective for monosomy X (Turner syndrome), but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Beta-thalassemia and related hemoglobinopathies (the Singapore licence text is blank, so this comes from the knowledge-graph indication edges) |
| Predicted New Indication | Monosomy X |
| TxGNN Prediction Score | 96.00% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, luspatercept is an activin receptor type IIB ligand trap. It acts on the TGF-beta superfamily (SMAD2/3 signalling) and promotes late-stage red blood cell maturation. This explains its use in beta-thalassemia, where ineffective erythropoiesis drives anaemia and transfusion dependence.
No clear mechanistic link to monosomy X (Turner syndrome) is evident. Turner syndrome is a chromosomal disorder, mainly characterised by ovarian insufficiency, short stature and cardiovascular features. It is not primarily a disorder of erythroid maturation. The high score is therefore most likely a network-level artefact of the knowledge graph rather than a therapeutic rationale.
Other top-ranked predictions are also weakly supported. Most (hepatic infarction, hepatic veno-occlusive disease, peliosis hepatis, combined immunodeficiency, familial apolipoprotein C-II deficiency, adenosine deaminase deficiency, Hb Bart's hydrops fetalis) have no plausible mechanism. Several carry potential safety concerns, such as thromboembolic risk in hepatic vascular conditions and embryo-fetal toxicity for Hb Bart's hydrops fetalis.
Two lower-ranked predictions are biologically more plausible as research questions:
- Pyruvate kinase deficiency of red cells (score 93.8%): a hereditary haemolytic anaemia with ineffective erythropoiesis, which is mechanistically close to the approved use.
- Thalassemia, beta+, silent allele (score 93.3%): largely a rediscovery of the existing indication. Silent carriers are typically asymptomatic, so there is little rationale for treatment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16470P | REBLOZYL Powder for Solution for Injection 25 mg/vial | Injection, powder, for solution | Not stated in the data compiled |
| SIN16471P | REBLOZYL Powder for Solution for Injection 75 mg/vial | Injection, powder, for solution | Not stated in the data compiled |
Safety Considerations
- Drug Interactions: No interactions were found in the data compiled for this report.
Please refer to the package insert for other safety information. Based on the label, luspatercept carries a thromboembolic risk and embryo-fetal toxicity warnings. Both are relevant to the hepatic and fetal-related predictions above.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for monosomy X rests only on a model score, with no trials, no literature and no plausible mechanistic link. The Singapore licence data also lack approved-indication text and package insert warnings, so safety screening cannot proceed.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Detailed mechanism of action data (for example, from DrugBank)
- A dedicated literature and trial search for monosomy X
- A separate literature and trial search for pyruvate kinase deficiency, which is the most biologically plausible research question among the predictions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.